美国肾移植受者ST段抬高型心肌梗死的管理与结局
该研究利用美国全国住院患者样本数据库,纳入2003年至2013年因STEMI住院的成人,比较非慢性肾病组、5D期慢性肾病组与肾移植组的院内再灌注率和结局,发现肾移植组再灌注率高于5D期慢性肾病组但低于非慢性肾病组,风险校正院内死亡率低于5D期慢性肾病组、与非慢性肾病组相似。
要点
- 肾移植组STEMI患者院内再灌注率65.2%,高于5D期慢性肾病组的39.5%,低于非慢性肾病组的68.9%。
- 肾移植组风险校正院内死亡率低于5D期慢性肾病组(AOR 0.37,95%CI 0.33-0.43,P<.001)。
- 肾移植组风险校正院内死亡率与非慢性肾病组相似(AOR 1.14,95%CI 0.99-1.31,P=.08)。
核心结论
- 肾移植受者发生STEMI的院内死亡率优于5D期慢性肾病患者,并接近一般人群STEMI患者。
研究设计与样本
- 研究查询美国全国住院患者样本数据库,识别18岁及以上以STEMI为主要诊断住院的患者,纳入2003年1月1日至2013年12月31日美国所有STEMI住院。
- 研究使用国际疾病分类第九版临床修改编码将患者分为非慢性肾病组、5D期慢性肾病组和既往肾移植组,数据分析于2016年3月至5月进行。
主要发现
- 2003年至2013年共识别非慢性肾病组2 319 002例(女性34.7%,男性65.3%,平均[SD]年龄64.2[14.4]岁)、5D期慢性肾病组30 072例(女性45.0%,男性55.0%,平均[SD]年龄66.9[12.5]岁)和肾移植组2 980例(女性27.3%,男性72.7%,平均[SD]年龄57.5[11.1]岁)因STEMI住院。
- 非慢性肾病组68.9%、5D期慢性肾病组39.5%、肾移植组65.2%的患者接受了院内再灌注治疗。
- 肾移植组接受再灌注的可能性高于5D期慢性肾病组(AOR 1.83,95%CI 1.67-2.01,P<.001),但低于非慢性肾病组(AOR 0.75,95%CI 0.68-0.83,P<.001)。
- 肾移植组风险校正院内死亡率明显低于5D期慢性肾病组(AOR 0.37,95%CI 0.33-0.43,P<.001),与非慢性肾病组相似(AOR 1.14,95%CI 0.99-1.31,P=.08)。
- 肾移植受者中,再灌注使用率从2003-2004年间的53.7%增至2011-2013年间的81.4%(趋势检验AOR 1.33,95%CI 1.25-1.43,P<.001),而风险校正院内死亡率从2003-2004年间的8.9%至2011-2013年间的6.1%保持不变(趋势检验AOR 0.94,95%CI 0.85-1.05,P=.27)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Renal transplantation is associated with reduction in the risk for myocardial infarction (MI) in patients with chronic kidney disease requiring long-term dialysis (stage 5D CKD). Whether outcomes of MI differ among renal transplant recipients vs patients with stage 5D CKD or those without CKD has not been well examined. OBJECTIVES: To compare in-hospital reperfusion rates and outcomes of ST-segment elevation MI (STEMI) in renal transplant recipients vs the stage 5D CKD group or the non-CKD group. DESIGN, SETTING, AND PARTICIPANTS: The National Inpatient Sample database was queried to identify patients 18 years or older who were hospitalized with the principal diagnosis of STEMI. All hospitalizations for STEMI in the United States from January 1, 2003, to December 31, 2013, were included. Codes from International Classification of Diseases, Ninth Revision, Clinical Modification, were used to identify patients in the non-CKD, stage 5D CKD, or prior renal transplant groups. Data were analyzed from March to May 2016. MAIN OUTCOMES AND MEASURES: In-hospital mortality. RESULTS: From 2003 to 2013, 2 319 002 patients in the non-CKD group (34.7% women; 65.3% men; mean [SD] age, 64.2 [14.4] years), 30 072 patients in the stage 5D CKD group (45.0% women; 55.0% men; mean [SD] age, 66.9 [12.5] years), and 2980 patients in the renal transplant group (27.3% women; 72.7% men; mean [SD] age, 57.5 [11.1] years) were identified who were hospitalized with STEMI. Of these, 68.9% of the patients in the non-CKD group, 39.5% in the stage 5D CKD group, and 65.2% in the renal transplant group received in-hospital reperfusion for STEMI. The renal transplant group was more likely to receive reperfusion compared with the stage 5D CKD group (adjusted odds ratio [AOR], 1.83; 95% CI, 1.67-2.01; P < .001) but less likely compared with the non-CKD group (AOR, 0.75; 95% CI, 0.68-0.83; P < .001). Risk-adjusted in-hospital mortality among the renal transplant group with STEMI was markedly lower compared with the stage 5D CKD group (AOR, 0.37; 95% CI, 0.33-0.43; P < .001) but similar compared with the non-CKD group (AOR, 1.14; 95% CI, 0.99-1.31; P = .08). Among renal transplant recipients with STEMI, the use of reperfusion increased from 53.7% in the 2003-2004 interval to 81.4% in the 2011-2013 interval (AOR, 1.33; 95% CI, 1.25-1.43; P < .001 for trend), whereas risk-adjusted in-hospital mortality remained unchanged during the study period, from 8.9% in the 2003-2004 interval to 6.1% in the 2011-2013 interval (AOR, 0.94; 95% CI, 0.85-1.05; P = .27 for trend). CONCLUSIONS AND RELEVANCE: In-hospital mortality rates in renal transplant recipients with STEMI are more favorable compared with those of patients with stage 5D CKD and approach those of the general population with STEMI.
引用
- Gupta T, Kolte D, Khera S, et al. Management and Outcomes of ST-Segment Elevation Myocardial Infarction in US Renal Transplant Recipients. JAMA Cardiol. 2017. PMID: 28097322. doi:10.1001/jamacardio.2016.5131
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。